Merck KGaA, Darmstadt, Germany, has agreed to acquire Bio-Techne for approximately $11.3 billion, a strategic move aimed at enhancing its leadership in the life science value chain. This acquisition will bolster Merck’s presence in high-growth markets by integrating Bio-Techne’s advanced tools, analytical technologies, and consumables into its existing platforms and services, thereby supporting a comprehensive workflow from research to commercial manufacturing.
The addition of Bio-Techne’s multiomics offerings and innovative solutions aligns with Merck KGaA’s mid- to long-term strategic agenda, which emphasizes growth through mergers and acquisitions. This deal is part of a broader trend, as Merck KGaA has engaged in over $35 billion worth of acquisitions in recent years, signaling its commitment to scaling innovation and enhancing its competitive position in the life sciences sector.
Expected to close by late 2026 or early 2027, the acquisition is projected to yield significant financial benefits, including immediate accretion to EBITDA margins and an estimated €140 million in synergies by the third year post-acquisition. As the third largest biopharma M&A deal of the year, this transaction underscores the ongoing consolidation in the industry, positioning Merck KGaA and Bio-Techne to drive future scientific advancements and therapeutic innovations.
Use the database as your supply chain compass →
